Abstract:Yanli Wang, 1 Yan Liu, 1, 2 Yongle Wang, 1, 3 Ping Bai, 1 Madelyn Rose Hallisey, 1 Breanna Lizeth Varela, 1 Anne Siewko, 1 Changning Wang, 1 Yulong Xu 1 1 Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; 2 School of Pharmacy, Lanzhou University, Lanzhou, Gansu, 730000, People's Republic of China; 3 School of Pharmacy, Minzu University of China, Beijing, 100081, People's Republic of China Correspondence: Yulong Xu; Changning Wang, Email ; Introduction: Sirtuins (SIRTs) comprise a group of histone deacetylase enzymes crucial for regulating metabolic pathways and contributing significantly to various disease mechanisms. Sirtuin 1 (SIRT1), among the seven known mammalian homologs, is extensively investigated and understood, playing a key role in neurodegenerative disorders and cancer. This study focuses on potential as a therapeutic target for conditions such as Parkinson's disease (PD), Huntington's disease (HD), and Alzheimer's disease (AD). Methods: Utilizing positron emission tomography (PET) as a noninvasive molecular imaging modality, we aimed to expedite the validation of a promising sirtuin 1 inhibitor for clinical trials. However, the absence of a validated sirtuin 1 PET radiotracer impedes clinical translation. We present the development of [ 11 C] 1 , and 11 C-labeled benzoxazine-based derivative, as a lead imaging probe. The radiosynthesis of [ 11 C] 1 resulted in a radiochemical yield of 31 ± 4%. Results: Baseline studies demonstrated that [ 11 C] 1 exhibited excellent blood-brain barrier (BBB) penetration capability, with uniform accumulation throughout various brain regions. Self-blocking studies revealed that introducing an unlabeled compound 1 , effectively blocking sirtuin 1, led to a substantial reduction in whole-brain uptake, emphasizing the in vivo specificity of [ 11 C] 1 for sirtuin 1. Discussion: The development of [ 11 C] 1 provides a valuable tool for noninvasive imaging investigations in rodent models with aberrant sirtuin 1 expression. This novel radiotracer holds promise for advancing our understanding of sirtuin 1's role in disease mechanisms and may facilitate the validation of sirtuin 1 inhibitors in clinical trials. Keywords: sirtuin 1, neuroimaging, benzoxazine-based derivative, blood-brain barrier Sirtuins, as nicotinamide adenine dinucleotide (NAD + )-dependent deacetylases, play a pivotal role in deacetylating diverse protein substrates, including transcription factors and histones. 1 The broad involvement of sirtuins in numerous physiological processes highlights their significant biological relevance. Within the sirtuin family, comprised of seven known members (sirtuin 1–7), each subtype exhibits distinct localization and functions. Notably, sirtuin 1 has garnered substantial attention over the past two decades, primarily due to its association with increased longevity. 2 Extensive evidence suggests that sirtuin 1 plays a role in normal cell development, inflammatory responses, and energy metabolism, making it a potential therapeutic target for addressing age-related diseases, including neurodegenerative disorders and cancer. 3–5 To date, various chemical modulators targeting sirtuin 1 have been developed, encompassing both activators and inhibitors. Sirtuin 1 (SIRT1) activators and inhibitors employ distinct mechanisms to modulate the activity and function of the SIRT1 enzyme. Activators enhance SIRT1's enzymatic activity by interacting with the enzyme, thereby increasing its binding affinity to substrates such as histones and other proteins. Additionally, some activators may induce the upregulation of SIRT1 expression, resulting in elevated enzyme levels. These actions contribute to physiological benefits, including improved metabolic function and potential longevity. Conversely, SIRT1 inhibitors suppress the enzymatic activity of SIRT1 by binding to its catalytic site, preventing the deacetylation of target proteins. The dynamic regulation of the SIRT1 enzyme by both activators and inhibitors influences various cellular pathways and processes in a context-dependent manner. 6 Sirtuin 1 activators, such as resveratrol and SRT1720, have demonstrated protective effects against conditions like diabetes, obesity-induced fatty liver, and insulin resistance. Nonetheless, several limitations hinder the practical applications of these activat -Abstract Truncated-

Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults

Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial

Possible effect of the cell synchronization method on the pattern of 5-bromodeoxyuridine incorporation into early synthesized DNA.

Design, synthesis, and pharmacological evaluations of pyrrolo[1,2- a ]quinoxaline-based derivatives as potent and selective sirt6 activators

First-in-human Phase 1 Study of SPH4336, a Novel Cyclin-Dependent Kinase 4/6 Inhibitor, in Patients with Advanced Solid Tumors.

Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers

Emerging roles of SIRT1 activator, SRT2104, in disease treatment

Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect

Discovery of small molecule sirt1 activator using high-throughput virtual screening, molecular dynamics simulation, molecular mechanics generalized born/surface area (MM/GBSA) calculation, and biological evaluation

Design, synthesis, and biological screening of a series of pyrazolo [1,5-a]quina-zoline derivatives as SIRT6 activators

Development and Characterization of a Novel Carbon-11 Labeled Positron Emission Tomography Radiotracer for Neuroimaging of Sirtuin 1 with Benzoxazine-Based Compounds

763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study

A Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and central nervous system activity of CY6463 when administered to participants with Alzheimer’s disease with vascular pathology

Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese Subjects

A pharmacological review on SIRT 1 and SIRT 2 proteins, activators, and inhibitors: Call for further research

In silico screening of small molecule modulators and their binding studies against human sirtuin-6 protein

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants